Ascentage Pharma Entered into a Clinical Collaboration with Clover to Evaluate APG-1387 + SCB-313 for the Treatment of Peritoneal Carcinomatosis
- The companies collaborated to evaluate the safety, tolerability, PK/PD & efficacy of Ascentage’s APG-1387 + Clover's SCB-313 in a P-Ib/II study in patients with advanced peritoneal carcinomatosis
- The companies are expected that a combination of SCB-313 & APG-1387 will provide a synergistic benefit to patients. Ascentage is currently conducting multiple clinical studies of APG-1387 combinations for solid tumors in China & the US.
- Clover is planning to advance SCB-313 into a P-II trial for malignant ascites in H1’22, based on P-I interim analyses & also start P-I trials of SCB-313 for bladder cancer in 2022. APG-1387 is being evaluated in a P-II study for chronic HBV infections in China
Ref: Businesswire| Image: Ascentage
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at email@example.com